Ecolab is ramping up its global life sciences ambitions with the launch of its first Asian bioprocessing facility, opening a new Bioprocessing Applications Lab (BPAL) in Dongtan, South Korea.

 

The move marks a major expansion of the company’s Life Sciences business as it looks to support the fast-growing biopharmaceutical sector across Asia, particularly in advanced manufacturing markets like South Korea.

 

“Building on the continued growth and strong performance of its Life Sciences business, Ecolab is further expanding its global bioprocessing capabilities to support biopharmaceutical manufacturers worldwide,” the company said in announcing the facility.

 

The new BPAL in Korea adds to Ecolab’s existing network in the United States and the United Kingdom, and is designed to support everything from early-stage process development to manufacturing-scale simulation. The goal is to help customers fine-tune purification processes, improve efficiency, and accelerate the path to commercial production.

 

“The facility enables hands-on collaboration with Ecolab’s bioprocessing experts to help customers optimize purification processes, enhance cost and process efficiency, and advance programs toward commercial readiness,” the company said.

 

South Korea has become a key global hub for biopharmaceutical production, especially in biosimilars, where speed, precision, and regulatory alignment are critical. By placing experts locally, Ecolab aims to reduce the need for overseas material transfers and help manufacturers move faster while maintaining consistency across global operations.

 

“Biopharmaceutical manufacturers across Asia are under increasing pressure to scale with speed while meeting demanding regulatory and performance expectations,” said Jenny Tan, vice president and general manager, Ecolab Life Sciences APAC and India. 

 

“BPAL Korea strengthens our ability to work side by side with customers, bringing deep local expertise together with Ecolab’s global, integrated bioprocessing network.”

 

The company framed the investment as part of a broader long-term strategy to expand its life sciences footprint and strengthen its bioprocessing technologies, including its affinity resin portfolio.

 

“BPAL Korea is the latest example of Ecolab Life Sciences’ long-term investment in the life sciences industry,” the company said, highlighting its continued push to build a global network of development and applications centers.

 

Ecolab, which operates in more than 170 countries, said the expansion supports its broader mission of enabling safer, more efficient drug development and manufacturing at scale.